ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "b5842431-dd5f-4e04-806d-87060e3ee26c"}, "_deposit": {"id": "33910", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "33910"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00033910", "sets": ["455", "562"]}, "item_6_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "SGLT2阻害薬はメダカNASHモデルにおいて肝の線維化を遅らせた"}]}, "item_6_date_granted_51": {"attribute_name": "学位授与年月日", "attribute_value_mlt": [{"subitem_dategranted": "2019-09-20"}]}, "item_6_degree_grantor_49": {"attribute_name": "学位授与機関", "attribute_value_mlt": [{"subitem_degreegrantor": [{"subitem_degreegrantor_name": "新潟大学"}]}]}, "item_6_degree_name_48": {"attribute_name": "学位名", "attribute_value_mlt": [{"subitem_degreename": "博士(医学)"}]}, "item_6_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested for its therapeutic effect on NASH; however, no studies to date have demonstrated the preventive effect of an SGLT2 inhibitor on the histological progression of steatosis and fibrosis in a sequential manner in animal models. In the present study, we examined the effect of the SGLT2 inhibitor, tofogliflozin (Tofo), on NASH liver tissue using medaka as an animal model, maintaining a feeding amount and drug concentration in all animal bodies. We generated a medaka NASH model by feeding d-rR/Tokyo medaka a high-fat diet and administered Tofo by dissolving the drug directly in the water of the feeding tank. Thereafter, the effects of Tofo on body weight (BW), liver weight, hepatotoxicity, fatty infiltration, and fibrotic changes in the liver were examined. We report here that SGLT2 is expressed in medaka fish and that Tofo inhibits the accumulation of fatty tissue and delays the progression of liver fibrosis in the medaka NASH model by inhibiting increases in blood sugar, serum lipids, and transaminase, irrespective of changes in BW. These results suggest that Tofo is effective for treating NASH and that the medaka model may be useful for developing new therapeutic drugs for this disease.", "subitem_description_type": "Abstract"}]}, "item_6_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "FEBS Open Bio. 2019, 9(4), 643-652.", "subitem_description_type": "Other"}]}, "item_6_description_53": {"attribute_name": "学位記番号", "attribute_value_mlt": [{"subitem_description": "新大院博(医)甲第886号", "subitem_description_type": "Other"}]}, "item_6_dissertation_number_52": {"attribute_name": "学位授与番号", "attribute_value_mlt": [{"subitem_dissertationnumber": "13101甲第4626号"}]}, "item_6_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "177866", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "後藤, 諒"}]}]}, "item_6_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "info:doi/10.1002/2211-5463.12598", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_15": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "FEBS Open Bio (2019) 【○!C】 2019 The Authors. Published by FEBS Press and John Wiley \u0026 Sons Ltd."}]}, "item_6_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "ETD"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Goto, Ryo"}], "nameIdentifiers": [{"nameIdentifier": "177865", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-07-08"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "r1nmk886.pdf", "filesize": [{"value": "1.1 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1100000.0, "url": {"label": "本文", "url": "https://niigata-u.repo.nii.ac.jp/record/33910/files/r1nmk886.pdf"}, "version_id": "2078bdce-dd4b-45dc-8378-96fec8891d77"}, {"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-07-08"}], "displaytype": "detail", "download_preview_message": "", "file_order": 1, "filename": "r1nmk886_a.pdf", "filesize": [{"value": "566.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 566400.0, "url": {"label": "要旨", "url": "https://niigata-u.repo.nii.ac.jp/record/33910/files/r1nmk886_a.pdf"}, "version_id": "85c0da39-a77a-49f6-ba2f-98754b0c50c5"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "d-rR/Tokyo medaka", "subitem_subject_scheme": "Other"}, {"subitem_subject": "liver fibrosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "NASH", "subitem_subject_scheme": "Other"}, {"subitem_subject": "SGLT2", "subitem_subject_scheme": "Other"}, {"subitem_subject": "tofogliflozin", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "thesis", "resourceuri": "http://purl.org/coar/resource_type/c_46ec"}]}, "item_title": "Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)"}]}, "item_type_id": "6", "owner": "1", "path": ["455", "562"], "permalink_uri": "http://hdl.handle.net/10191/00051708", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-07-08"}, "publish_date": "2020-07-08", "publish_status": "0", "recid": "33910", "relation": {}, "relation_version_is_last": true, "title": ["Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)"], "weko_shared_id": null}
  1. 0 資料タイプ別
  2. 02 学位論文
  1. 250 大学院医歯学総合研究科(医)
  2. 60 博士学位論文
  3. 10 博士学位論文

Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)

http://hdl.handle.net/10191/00051708
http://hdl.handle.net/10191/00051708
3bbf8803-c8db-4057-9191-40c39cf280d9
名前 / ファイル ライセンス アクション
r1nmk886.pdf 本文 (1.1 MB)
r1nmk886_a.pdf 要旨 (566.4 kB)
Item type 学位論文 / Thesis or Dissertation(1)
公開日 2020-07-08
タイトル
タイトル Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)
言語
言語 eng
キーワード
主題Scheme Other
主題 d-rR/Tokyo medaka
キーワード
主題Scheme Other
主題 liver fibrosis
キーワード
主題Scheme Other
主題 NASH
キーワード
主題Scheme Other
主題 SGLT2
キーワード
主題Scheme Other
主題 tofogliflozin
資源タイプ
資源 http://purl.org/coar/resource_type/c_46ec
タイプ thesis
その他のタイトル
その他のタイトル SGLT2阻害薬はメダカNASHモデルにおいて肝の線維化を遅らせた
著者 Goto, Ryo

× Goto, Ryo

WEKO 177865

Goto, Ryo

Search repository
著者別名
識別子 177866
識別子Scheme WEKO
姓名 後藤, 諒
抄録
内容記述タイプ Abstract
内容記述 The rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested for its therapeutic effect on NASH; however, no studies to date have demonstrated the preventive effect of an SGLT2 inhibitor on the histological progression of steatosis and fibrosis in a sequential manner in animal models. In the present study, we examined the effect of the SGLT2 inhibitor, tofogliflozin (Tofo), on NASH liver tissue using medaka as an animal model, maintaining a feeding amount and drug concentration in all animal bodies. We generated a medaka NASH model by feeding d-rR/Tokyo medaka a high-fat diet and administered Tofo by dissolving the drug directly in the water of the feeding tank. Thereafter, the effects of Tofo on body weight (BW), liver weight, hepatotoxicity, fatty infiltration, and fibrotic changes in the liver were examined. We report here that SGLT2 is expressed in medaka fish and that Tofo inhibits the accumulation of fatty tissue and delays the progression of liver fibrosis in the medaka NASH model by inhibiting increases in blood sugar, serum lipids, and transaminase, irrespective of changes in BW. These results suggest that Tofo is effective for treating NASH and that the medaka model may be useful for developing new therapeutic drugs for this disease.
内容記述
内容記述タイプ Other
内容記述 FEBS Open Bio. 2019, 9(4), 643-652.
DOI
識別子タイプ DOI
関連識別子 info:doi/10.1002/2211-5463.12598
権利
権利情報 FEBS Open Bio (2019) 【○!C】 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
著者版フラグ
値 ETD
学位名
学位名 博士(医学)
学位授与機関
学位授与機関名 新潟大学
学位授与年月日
学位授与年月日 2019-09-20
学位授与番号
学位授与番号 13101甲第4626号
学位記番号
内容記述タイプ Other
内容記述 新大院博(医)甲第886号
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 08:09:14.398053
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3